SOPHiA GENETICS (SOPH) EBITDA (2020 - 2025)

SOPHiA GENETICS (SOPH) has 6 years of EBITDA data on file, last reported at -$18.5 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA fell 104.57% year-over-year to -$18.5 million; the trailing twelve-month figure through Dec 2025 stood at -$70.9 million (down 21.88% YoY), and the FY2025 full-year result was -$70.9 million, down 76.48% from the prior year.
• EBITDA declined to -$18.5 million in Q4 2025, from -$17.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$9.1 million in Q4 2024 to a low of -$25.0 million in Q1 2022.
• A 5-year average of -$17.8 million and a median of -$18.2 million in 2025 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 99.77% in 2021, while the deepest fall reached 217289.46% in 2021.
• Tracing SOPH's EBITDA over 5 years: stood at -$21.0 million in 2021, then increased by 28.21% to -$15.1 million in 2022, then increased by 19.47% to -$12.1 million in 2023, then rose by 25.49% to -$9.1 million in 2024, then tumbled by 104.57% to -$18.5 million in 2025.
• Business Quant data shows SOPH's EBITDA at -$18.5 million in Q4 2025, -$17.9 million in Q3 2025, and -$18.5 million in Q2 2025.